Search research articles
Contact Us
Filters
Showing results (241-250 of 306) with videos related to
Page
of 31
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 8, 2001
Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia
S D Gore, L J Weng, S Zhai, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
February 8, 2021
Challenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid Malignancies
Rory M Shallis, Jan Philipp Bewersdorf, David M Swoboda, et al.
JNCI Cancer Spectrum
|
December 16, 2022
Expanding access to early phase trials: the CATCH-UP.2020 experience
Joaquina C Baranda, Francisco J Diaz, Larry Rubinstein, et al.
British Journal of Haematology
|
November 19, 2015
Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study
Thomas Prebet, Zhuoxin Sun, Rhett P Ketterling, et al.
British Journal of Haematology
|
May 19, 2012
Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias
Amer M Zeidan, Rebecca M Ricklis, Hetty E Carraway, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 3, 2005
Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias
Judith E Karp, Antonino Passaniti, Ivana Gojo, et al.
Leukemia Research
|
December 8, 2009
Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia
Judith E Karp, Amanda Blackford, B Douglas Smith, et al.
Blood
|
April 13, 2006
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Bruce D Cheson, Peter L Greenberg, John M Bennett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 26, 2014
Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905
Thomas Prebet, Zhuoxin Sun, Maria E Figueroa, et al.
British Journal of Haematology
|
February 18, 2014
Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy
Steven E Coutre, Megan Othus, Bayard Powell, et al.
Page
of 31
Search research articles
Search
Showing results (241-250 of 306) with videos related to
Sort By:
Page
of 31
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 8, 2001
Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia
S D Gore, L J Weng, S Zhai, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
February 8, 2021
Challenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid Malignancies
Rory M Shallis, Jan Philipp Bewersdorf, David M Swoboda, et al.
JNCI Cancer Spectrum
|
December 16, 2022
Expanding access to early phase trials: the CATCH-UP.2020 experience
Joaquina C Baranda, Francisco J Diaz, Larry Rubinstein, et al.
British Journal of Haematology
|
November 19, 2015
Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study
Thomas Prebet, Zhuoxin Sun, Rhett P Ketterling, et al.
British Journal of Haematology
|
May 19, 2012
Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias
Amer M Zeidan, Rebecca M Ricklis, Hetty E Carraway, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 3, 2005
Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias
Judith E Karp, Antonino Passaniti, Ivana Gojo, et al.
Leukemia Research
|
December 8, 2009
Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia
Judith E Karp, Amanda Blackford, B Douglas Smith, et al.
Blood
|
April 13, 2006
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Bruce D Cheson, Peter L Greenberg, John M Bennett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 26, 2014
Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905
Thomas Prebet, Zhuoxin Sun, Maria E Figueroa, et al.
British Journal of Haematology
|
February 18, 2014
Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy
Steven E Coutre, Megan Othus, Bayard Powell, et al.
Page
of 31